Form 4: Terns Pharmaceuticals Director Sells Shares to Cover Tax Obligations and Under Pre-Arranged Trading Plan

Terns Pharmaceuticals director Jill M. Quigley sold shares of common stock to cover tax obligations and under a pre-arranged trading plan.

Summary

• Jill M. Quigley, a director at Terns Pharmaceuticals, sold 6,240 shares of common stock on January 2, 2025, at a weighted average price of $5.7215 per share.
• These shares were sold to cover taxes associated with the vesting of a restricted stock unit award.
• The sale was not a discretionary trade by the director.
• Additionally, on January 6, 2025, Ms. Quigley sold 8,760 shares of common stock at a weighted average price of $5.7943 per share.
• This second sale was executed under a Rule 10b5-1 trading plan adopted on March 18, 2024.
• The weighted average sale prices for both transactions represent a range of prices at which the shares were sold.

Sentiment

Score: 5

Explanation: The document reflects routine insider trading activity, which is neither positive nor negative for the company's overall prospects. The sales were pre-planned and for tax purposes, not a reflection of the director's view of the company's future.

Industry Context

This is a routine filing related to insider trading activity, which is common for directors and officers of publicly traded companies. The use of a 10b5-1 trading plan is a common practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of Rule 10b5-1 trading plans is a standard practice among corporate insiders to manage their stock sales and avoid potential insider trading issues.
• Similar filings are regularly made by directors and officers of other publicly traded companies, such as those in the biotechnology sector like Gilead Sciences or Amgen, when they sell shares.
• The reported price ranges are typical for transactions of this nature, reflecting the market price at the time of the sales.

Stakeholder Impact

• The share sales may have a minor impact on the stock price, but are unlikely to significantly affect the company's operations or long-term prospects.
• Shareholders may view the sales as routine transactions by a director.

Key Dates

Keywords

Terns Pharmaceuticals, insider trading, stock sale, Form 4, Rule 10b5-1, director, share sale, equity securities